COGNITION, FUNCTION AND GENOTYPE IN ALZHEIMERS DISEASE

阿尔茨海默病(AD)是一种成人发病的神经退行性疾病， 影响了400多万美国人及其家人。广告是 以疾病进展速度的不确定性为特征的 由于它的认知和功能表现，阻碍了能力 以预测资源使用情况并指定干预措施。 不确定性也可能对职业和家庭照顾者造成影响 压力。最近的研究表明， 载脂蛋白E基因与阿尔茨海默病及其潜在的载脂蛋白E 通过α1-抗糜蛋白酶(ACT)基因的修饰作用，提供 生物学标志物在AD的诊断和预后中具有潜在的应用价值。 需要进一步的研究来了解载脂蛋白E与 基因状态和潜在的修饰基因、发病年龄、疾病 进展，以及认知和功能障碍的模式，作为 减少AD患者的不确定性的方法，他们的 家庭和专业的照顾者。这项研究提出了 收集家族病史、APOE基因和ACT基因数据以 与两个现有的护理研究数据库链接，其中包括 重复测量认知、非认知和功能状态 AD受试者：家庭参与护理(FIC)数据集和 逐步降低应激阈值(PLST)数据集。的目的 本研究的目的是：1)描述APOE和ACT等位基因的分布 阿尔茨海默病患者的频率及其与已知等位基因频率的比较 在一般人群中，2)分析APOE与 ACT基因分型和发病年龄、认知和功能比率 下降，以及认知、非认知和功能性的概况 阿尔茨海默病的表现。

Alzheimer's disease (AD), an adult-onset, neurodegenerative disorder, affects more than 4 million Americans and their families. AD is characterized by uncertainty in the rate of disease progression as well as its cognitive and functional manifestations, hindering the ability of nurses to predict resource use and specify interventions. Uncertainty may also contribute to professional and family caregiver stress. Recent research demonstrates an association between apolipoprotein E (APOE) genotype and AD as well as a potential APOE modifying effect by the alpha1-antichymotrypsin (ACT) gene, providing biological markers with potential utility in AD diagnosis and prognosis. Further research is needed to understand the association between APOE gene status and potential modifier genes, age of onset, disease progression, and patterns of cognitive and functional impairment, as a means of reducing uncertainty for the individuals with AD, their families, and professional caregivers. This study proposes the collection of family history, APOE genotype, and ACT genotype data to be linked with two existing nursing research databases containing repeated measures of cognitive, non-cognitive, and functional status for subjects with AD: the Family Involvement in Care (FIC) dataset and the Progressively Lowered Stress Threshold (PLST) dataset. The purposes of this study are to: 1) describe the distribution of APOE and ACT allele frequencies among people with AD and compare to known allele frequencies in the general population, and 2) analyze the relationship between APOE and ACT genotypes and age of onset, rate of cognitive and functional decline, and profiles of cognitive, non-cognitive, and functional manifestations in AD.